vTv Therapeutics announces participation in September investor conferences, focusing on cadisegliatin for type 1 diabetes treatment.
Quiver AI Summary
vTv Therapeutics Inc. announced its participation in two investor conferences in September 2025, including the H.C. Wainwright 27th Annual Global Investment Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference. The company is focused on developing cadisegliatin, a novel oral therapy for type 1 diabetes currently in Phase 3 trials. As a late-stage biopharmaceutical firm, vTv is dedicated to creating small molecule drug candidates for diabetes and other chronic diseases, with a range of molecules under investigation for various indications. For more information, investors and the media can reach out to designated contacts listed in the release.
Potential Positives
- vTv Therapeutics is advancing a novel therapy, cadisegliatin, which has the potential to be a first-in-class treatment for type 1 diabetes, indicating significant innovation in their product pipeline.
- The participation in prominent investor conferences may enhance investor interest and confidence, providing opportunities for funding and collaboration.
- Cadisegliatin is currently in Phase 3 trials, demonstrating progress in clinical development that could lead to potential future market introduction.
- The company's focus on developing treatments for chronic diseases highlights its commitment to addressing significant healthcare needs, potentially increasing its market appeal and impact.
Potential Negatives
- The release does not provide any updates on the progress or results of cadisegliatin's Phase 3 trial, which could raise concerns about the drug's development timeline or effectiveness.
- The focus on investor conferences suggests that the company may be under pressure to secure funding or generate investor interest, indicating potential financial instability.
- There is no mention of any new partnerships or collaborations, which may imply a lack of strategic advancement in their drug development initiatives.
FAQ
What is cadisegliatin and its purpose?
Cadisegliatin is a novel oral adjunctive therapy to insulin being developed for treating type 1 diabetes.
When will vTv Therapeutics present at investor conferences?
vTv Therapeutics will present at the H.C. Wainwright Conference on September 9, 2025, and the Morgan Stanley Conference on September 10, 2025.
What is the current status of cadisegliatin?
Cadisegliatin is currently in a Phase 3 trial for its potential effectiveness in treating type 1 diabetes.
How can I learn more about vTv Therapeutics?
You can learn more by visiting vtvtherapeutics.com or following the company on LinkedIn or X.
Who should I contact for investor inquiries?
For investor inquiries, you can contact John Fraunces at LifeSci Advisors via email at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VTVT Hedge Fund Activity
We have seen 8 institutional investors add shares of $VTVT stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 15,042 shares (+inf%) to their portfolio in Q2 2025, for an estimated $225,630
- VANGUARD GROUP INC added 1,617 shares (+3.9%) to their portfolio in Q2 2025, for an estimated $24,255
- UBS GROUP AG removed 1,193 shares (-29.5%) from their portfolio in Q2 2025, for an estimated $17,895
- TOWER RESEARCH CAPITAL LLC (TRC) removed 394 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $5,910
- NORTHERN TRUST CORP removed 339 shares (-2.2%) from their portfolio in Q2 2025, for an estimated $5,085
- CONNECTIVE CAPITAL MANAGEMENT, LLC added 335 shares (+3.6%) to their portfolio in Q2 2025, for an estimated $5,025
- GEODE CAPITAL MANAGEMENT, LLC added 229 shares (+1.8%) to their portfolio in Q2 2025, for an estimated $3,435
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$VTVT Analyst Ratings
Wall Street analysts have issued reports on $VTVT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 04/09/2025
To track analyst ratings and price targets for $VTVT, check out Quiver Quantitative's $VTVT forecast page.
Full Release
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:
|
H.C. Wainwright 27th Annual Global Investment Conference
|
|
| Date: | Tuesday, September 9, 2025 |
| Format: | 1x1 Investor Meetings Only |
| Morgan Stanley 23rd Annual Global Healthcare Conference | |
| Date: | Wednesday, September 10, 2025 |
| Format: | Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings |
About
vTv
Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by
cadisegliatin
, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at
vtvtherapeutics.com
or follow the company on
LinkedIn
or
X
.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
[email protected]
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
[email protected]
